Oxidative phosphorylation

Oxidative phosphorylation (OXPHOS) is the mitochondrial process of fully oxidizing fuel—primarily glucose—to carbon dioxide, water, and ATP, and its impairment is the central metabolic defect underlying cancer and virtually all chronic disease. 2 Peat argued that the efficiency of this coupling increases with higher evolutionary development and alertness, suggesting that a less wasteful use of oxygen is a crucial factor in longevity. 3 Dinkov has written that when forward electron flow through the OXPHOS complexes is blocked, reverse electron flow commences, generating an excess of reactive oxygen species (ROS); this occurs predominantly when metabolism is low or obstructed, not when it is high. 10 A properly functioning system, producing optimal amounts of CO₂ and water, generates negligible ROS because the rapid flow of electrons exerts a pulling effect that prevents electron leakage. 2

The degradation of OXPHOS is a common adaptive response to a hostile cellular environment. Dinkov explains that under chronic stress—whether from viral infection, poor diet, or environmental factors—the cell begins dismantling its oxidative apparatus, reverting to a primitive anaerobic energy production state identical to the Warburg effect seen in cancer. 2 This shift involves a loss of cellular differentiation; Dinkov notes that any differentiated cell can de-differentiate into a stem-like state if mitochondrial ROS production rises beyond a threshold, a finding that reframes cancer as a reversible metabolic condition rather than an irreversible genetic one. 10 Peat identified specific landmarks vulnerable to disruption, including phosphofructokinase-1 (PFK1), pyruvate dehydrogenase (PDH), and cytochrome c oxidase, with fat oxidation inherently biasing the system toward inefficiency by overproducing FADH₂ relative to NADH, which reduces the availability of ubiquinone at Complex I and backs up electron flow. 5

Estrogen and other stressors directly interfere with OXPHOS. Peat’s early work noted that estrogen’s action might occur through a disruption of oxidative phosphorylation, leading to altered intracellular potassium-to-sodium ratios and a phase change in cytoplasmic structure. 1 Dinkov has extended this by identifying specific interventions that restore electron flow through blocked complexes. The quinone coenzyme Q10, which is deficient in cancer patients, acts as a critical electron carrier, and other quinones like methylene blue can substitute for it, functioning as an oxidant that paradoxically acts as an antioxidant by enabling proper electron transit and preventing ROS formation. 2 B vitamins such as riboflavin, thiamine, and niacin serve as essential cofactors for the OXPHOS complexes, and their administration—along with agents like aspirin metabolites or pregnenolone—has shown promise in restoring oxidative metabolism in cancer cells without triggering the systemic inflammation caused by cytotoxic therapies. 2

The systemic consequences of OXPHOS failure extend beyond the initial site of injury. Dinkov describes how killing cancer cells with chemotherapy or radiation spills mitochondrial debris into the bloodstream, triggering inflammatory pathways that signal the entire body to shut down oxidative phosphorylation, thereby creating a permissive environment for metastatic dissemination. 8 This reinforces the principle that metabolic modulation—raising the low metabolic rate characteristic of disease—is the therapeutic goal, not cellular destruction. 10 Peat maintained that the faster the oxidative apparatus runs, the more it creates an electron-withdrawing effect that protects surrounding cells, making the maximally efficient production of CO₂ a form of structural insurance against degeneration. 5